ClinicalTrials.gg
CompletedNCT01433107Updated Dec 27, 2013Results posted

Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis

A Phase 3 interventional study of Terbinafine and Terbinafine Placebo in Tinea Pedis, sponsored by Novartis. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare the efficacy and safety of a single dose of terbinafine film forming solution 1% with a single dose of placebo film forming solution in the treatment of tinea pedis.

02

Conditions studied

  • Tinea Pedis

Browse trials for

Keywords

  • Tinea pedis
  • Terbinafine film forming solution
03

In context

Tinea Pedis

73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.

This study's enrollment of 290 is above the median of 128 across 66 interventional studies indexed under Tinea Pedis.

Browse Tinea Pedis studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years of age with interdigital tinea pedis infection, with clinical diagnosis meeting required baseline total sign \& symptom score and positive microscopy

Exclusion criteria

Exclusion Criteria:

  • Allergy to the allylamine class of antimycotics or in the formulation.
  • Chronic, hyperkeratotic plantar (moccasin) tinea pedis
  • Other fungal disease or intertrigo
  • Other abnormal findings on the affected foot
  • Systemic antifungal or antimicrobial treatment within the last 3 months
  • Topical treatment for skin lesions on feet within the last 3 months
  • Diabetes mellitus and peripheral artery occlusive disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    Terbinafine

    Drug

    Drug: Terbinafine

  • Placebo comparator
    Placebo

    Drug

    Drug: Terbinafine Placebo

Interventions

  • 1% single application

  • DrugTerbinafine Placebo

    single application

06

What researchers measure

Primary outcomes

  1. Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)

    Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptoms score the rating for all symptoms are added up. Possible range 0 to 18

    Time frame: week 6

Secondary outcomes

  1. Total Clinical Signs and Symptoms (S/S) Scores

    Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptom score, the scores for each individual symptom are added up. Possible range : 0 to 18

    Time frame: week 6

  2. Number of Subjects With Adverse Event

    Number of Subjects with adverse event

    Time frame: 6 weeks

07

Results

Posted Dec 27, 2013

Participant flow

Study start 27 Aug 2011 end 14 Feb 2012

Participant flow — Overall Study
MilestoneTerbinafinePlacebo
Started145145
Completed118128
Not completed2717

Outcome measures

PrimaryEffective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)

Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptoms score the rating for all symptoms are added up. Possible range 0 to 18

Time frame:
week 6
Reported as:
Number · participants
Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)
participantsTerbinafinePlacebo
Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)7310
SecondaryTotal Clinical Signs and Symptoms (S/S) Scores

Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptom score, the scores for each individual symptom are added up. Possible range : 0 to 18

Time frame:
week 6
Reported as:
Mean · units on a scale
Total Clinical Signs and Symptoms (S/S) Scores
units on a scaleTerbinafinePlacebo
Total Clinical Signs and Symptoms (S/S) Scores1.6 (1.3 to 2.0)4.7 (4.1 to 5.2)
SecondaryNumber of Subjects With Adverse Event

Number of Subjects with adverse event

Time frame:
6 weeks
Reported as:
Number · participants
Number of Subjects With Adverse Event
participantsTerbinafinePlacebo
Number of Subjects With Adverse Event911

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Terbinafine—0/146 (0%)0/146 (0%)
Placebo—0/144 (0%)7/144 (4.9%)
Most frequent other events
Most frequent other events
EventTerbinafinePlacebo
General DisordersGeneral disorders0/1467/144

Baseline characteristics

Age, Continuous
Age, Continuous(years)TerbinafinePlaceboTotal
Mean35.27 ± 12.80534.05 ± 11.93634.66 ± 12.372
Sex: Female, Male
Sex: Female, Male(Participants)TerbinafinePlaceboTotal
Female504696
Male9599194
08

Study locations

6 sites
  • Peking University First Hospital
    Beijing, 100034, China
  • Beijing University Hospital N°3
    Beijing, 100083, China
  • The Second Affiliated Hospital of Sun Yat-sen University Guangzhou
    Guangdong, 510120, China
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, 510630, China
  • Chinese Academy of Medical Sciences
    Jiangsu, 21004, China
  • Huashan Hospital, Fudan University
    Shanghai, 200040, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 13, 2011
Start
Aug 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Dec 27, 2013
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433107
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Aug 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Dec 27, 2013
Last update
Dec 27, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion